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Trp-His is the only vasoactive di-peptide known to regulate intracellular Ca2+ ([Ca2+]i) and prevent
the onset of atherosclerosis in mice. In this study, we showed that Trp-His reduced the [Ca2+]i eleva-
tion in phospholipase C-activated vascular smooth muscle cells (VSMCs), while a mixture of the cor-
responding constituent amino acids did not show signiﬁcant reduction. Furthermore, Trp-His
suppressed calmodulin-dependent kinase II (CaMK II) activity in angiotensin II-stimulated VSMCs,
resulting in the inhibition of phosphorylation of voltage-dependent L-type Ca2+ channels (VDCC).
Therefore, Trp-His potentially regulates the VDCC phosphorylation cascade through Ca2+-CaM/CaMK
II.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction As noted above, the anti-atherosclerotic di-peptide Trp-His alsoIn a series of our studies, we demonstrated that Trp-His [1], as
well as His-Arg-Trp [2], exhibited potent vasorelaxant and anti-
proliferative effects against vascular smooth muscle cells (VSMCs)
and were involved in the reduction of elevated intracellular Ca2+
level ([Ca2+]i) in VSMCs in part by their binding to an extracellular
site of voltage-dependent L-type Ca2+ channels (VDCC) [3]. To date,
except for these peptides, no endothelium-independent vasoactive
peptides have been reported, although peptides, such as
Arg-Ala-Asp-His-Pro [4] and Met-Tyr [5], have been reported to
evoke an endothelium-dependent relaxation. Our new ﬁndings
on the vasoactive functionality of small peptides allowed us to
investigate their potential role(s) in the prevention of hyperten-
sion-related vascular diseases, such as atherosclerosis, since the
onset is closely associated with the proliferation and/or migration
of VSMCs [6]. An oral administration study of Trp-His to apolipo-
protein E-deﬁcient mice clearly demonstrated the in vivo
vasoactivity of Trp-His, since 9 weeks of administration of
Trp-His (10 or 100 mg/kg/day) to mice inhibited progressive ath-
erosclerotic lesion without any alteration of the lipid proﬁles [7].cal Societies. Published by Elsevier




tsui).exhibited the ability to regulate elevation of [Ca2+]i in VSMCs. The
action was partly explained by its binding to VDCCs or inhibition of
extracellular Ca2+ inﬂux into VSMCs, since Trp-His reduced the
elevation of [Ca2+]i by a VDCC agonist (Bay K8644). However, it
was also found that the ability of Trp-His to reduce [Ca2+]i in Bay
K8644-stimulated VSMCs was one-quarter of that in angiotensin
II (Ang II)-stimulated VSMCs [3]. Ang II is known as one of the
major vasopressor hormones, and induces diverse intracellular
Ca2+-signaling transductions [8]. Therefore, it can be speculated
that greater effect of Trp-His to reduce [Ca2+]i in Ang II-VSMCs
may be caused by suppression of Ang II-related intracellular
Ca2+-signaling pathways in VSMCs, in addition to VDCC blocking
actions. In the present study, we demonstrate that Trp-His (and
not its individual constituent amino acids) inhibits phospholipase
C (PLC) activated-[Ca2+]i elevation in VSMCs and that the underly-
ing mechanism involves inhibition of calmodulin-dependent
kinase II (CaMK II) activity. The present study also provides the ﬁrst
evidence that Trp-His signiﬁcantly inhibits the phosphorylation of
VDCC, which pivotally regulates Ca2+ entry via VDCC in VSMCs,
suggesting a potential role of the anti-atherosclerotic di-peptide
Trp-His in the Ca2+-CaM/CaMK II-VDCC phosphorylation pathways.
2. Materials and methods
2.1. Materials
Trp-His was synthesized using an Fmoc-solid phase synthesis
method, according to the manufacturer’s instructions (KokusanB.V. Open access under CC BY-NC-ND license.
84 Y. Kobayashi et al. / FEBS Open Bio 2 (2012) 83–88Chemicals, Tokyo, Japan). Fura-2/AM was purchased from Dojindo
(Kumamoto, Japan). Angiotensin II (Ang II), S-(+)-PD 123177, 2-
aminoethoxydiphenyl borate (2-APB) and m-3M3FBS were
obtained from Sigma–Aldrich (St. Louis, MO, USA). U-73122 was
obtained from Merck (Darmstadt, Germany). RIPA buffer, Phos-
tag and KN-62 were purchased fromWako Pure Chemical Industry
(Osaka, Japan). Horseradish peroxidase (HRP) conjugated streptavi-
din and ECL prime detection reagents were obtained from GE
Healthcare Biosciences (Piscataway, NJ, USA).
2.2. Cell culture
Isolation of VSMCs from an 8 week-old male Wistar rat (Charles
River Japan, Kanagawa, Japan) and the cell culture were performed
according to our previous study [3]. The VSMCs were maintained at
37 C in a humidiﬁed 5% CO2 incubator. Passage numbers 5–7 were
used in this study. Animal experiments were carried out according
to the Guidance for Animal Experiments in the Faculty of Agricul-
ture and in the Graduate Course of Kyushu University and the Law
(No. 105, 1973) and Notiﬁcation (No. 6, 1980 of the Prime Minis-
ter’s Ofﬁce) of the Japanese Government.
2.3. Measurement of [Ca2+]i in VSMCs
Measurement of [Ca2+]i was performed using a Ca2+-sensitive
probe (Fura-2/AM), as described previously [3]. Brieﬂy, quiescent
VSMCs were incubated with 1 lM Fura-2/AM containing 0.1%
dimethylsulfoxide and 0.04% Cremophor EL (Nacalai Tesque, Kyoto,
Japan) in physiological salt solution (PSS, NaCl 145 mM, KCl 5 mM,
Na2HPO4 1 mM, CaCl2 2.5 mM, MgSO4 0.5 mM, glucose 10 mM, and
HEPES 5 mM, pH 7.4) for 60 min at 37 C. The cells (1  105 cells/
ml) were then added into a 3 ml-quartz cuvette, followed by pre-
treatment with Trp-His or inhibitors for 10 min at 37 C. Mitogen
(10 lM Ang II or 20 lM m-3M3FBS) was injected into the cuvette
and subsequent ﬂuorescence intensities were monitored using a
ﬂuorescence spectrophotometer (RF-5300PC, Shimadzu Co., Kyoto,
Japan). [Ca2+]i was calculated automatically at a dual excitation
wavelength of 340/380 nm and emission wavelength of 500 nm.
Unless otherwise noted, in Ang II-stimulation experiments,
1.0 lM PD123177 (an antagonist of angiotensin type 2 receptor
(AT2R)) [9] was added 10 min before the addition of Ang II to avoid
activation of vasorelaxation signaling pathways via AT2R or any
unexpected [Ca2+]i.
2.4. Extraction of the whole protein from Ang II-stimulated VSMCs
VSMCs (2  105 cells/well) were grown up to 90% conﬂuence in
6-well plates with DMEM (Invitrogen, Carlsbad, CA, USA) contain-
ing 10% fetal bovine serum (Invitrogen). Quiescent VSMCs were
pretreated with either vehicle or an inhibitor for 10 min, and then
incubated with either vehicle or Ang II (10 lM) in each well for
60 min at 37 C. After Ang II stimulation, the cells were washed
twice with ice cold PBS. The cells were then lysed in RIPA buffer
(150 mMNaCl, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) sodium
sulfate, 1.0% (w/v) NP-40 and 50 mM Tris–HCl, pH 8.0) and kept for
10 min on ice. The supernatant was collected following centrifuga-
tion at 20,000g for 15 min at 4 C and the protein concentration
was determined with a Bio-Rad DC Protein Assay Kit (using BSA
as a standard).
2.5. CaMK II activity in Ang II-stimulated VSMC extracts
The CaMK II activity in VSMCs was determined with an ELISA-
based kit (CycLex CaM Kinase II Assay Kit, MBL International,
Woburn, MA, USA) according to the manufacturer’s protocol.
Brieﬂy, 10 ll of the VSMC extract and 90 ll of the reaction mixture
containing 1 mM ATP were added to each well of a CaMK IIsubstrate-coated plate and incubated for 40 min at 30 C. The blank
for this assay contained an equal volume of RIPA buffer. After
washing ﬁve times with washing buffer, 100 ll of HRP conjugated
anti-phospho-substrate antibody was incubated for 60 min at
30 C. After additional washes, 100 ll of tetramethylbenzidine sub-
strate solution was incubated for 20 min at 30 C. The reaction was
stopped by adding 100 ll of the stop solution and the absorbance
at 450 nm was measured with a Wallac 1420-microplate reader
(Perkin Elmer Life Science, Tokyo, Japan). The CaMK II activity
(mU/mg protein) in VSMCs was calculated from standard curves
prepared with serial dilutions of CaMK II standard.
2.6. Preparation of Phos-tag
Phos-tag, a dinuclear metal complex (i.e., 1,3-bis[bis(pyridin-2-
ylmethyl)amino]propan-2-olato-di-zinc(II) complex), was pre-
pared according to the manufacturer’s instructions. Brieﬂy, 5 ll
of biotin-pendant Phos-tag (10 mM) was mixed with 20 ll of
Zn(NO3)2 (10 mM), 2 ll of HRP conjugated streptavidin and
473 ll of TBS-Tween20 (TBST, 20 mM Tris–HCl, 137 mM NaCl
and 0.05% Tween20, pH 7.6). This solution was allowed to stand
for 30 min at room temperature and then added to a centrifugal ﬁl-
ter device cup (nominal molecular weight cutoff = 30,000 Da, Mil-
lipore) and centrifuged at 14,000g for 10 min at room
temperature. The remaining solution in the cup was diluted with
10 ml of TBST, and used as the Phos-tag solution to detect the
amount of phosphorylated VDCC in Ang II-stimulated VSMCs.
2.7. Western blot analysis of phosphorylated VDCC
The determination of the amount of phosphorylation of VDCC
was performed with Western blot analysis using the Phos-tag
and anti-VDCC antibody on the samemembrane. The VSMC extract
was mixed with an equal volume of sample buffer (20% glycerol, 4%
sodium dodecyl sulfate (SDS), 3% dithiothreitol, 0.002% bromophe-
nol blue and 0.125 M Tris–HCl, pH 6.8) and incubated overnight at
4 C. An aliquot (15 lg/lane) of the sample-treated VSMC extract
was applied to 10% SDS–PAGE gels for 2 h at 20 mA and transferred
onto a PVDF membrane (Hybond-P, GE Healthcare) for 1.5 h at
40 mA. The membrane was incubated with the prepared
Phos-tag solution for 30 min at room temperature. After washing
twice for 5 min with TBST, the phosphorylated proteins on the
Phos-tag-labeled membrane were detected with ECL prime detec-
tion reagents and Image Quant LAS 4000 (GE Healthcare). For elim-
ination of the Phos-tag, the membrane was incubated in stripping
buffer (2% (w/v) SDS, 0.1 M mercaptoethanol and 62.5 mM Tris–
HCl, pH 6.8) for 30 min at room temperature and complete abolish-
ment of Phos-tag was conﬁrmed by the lack of detection of any
bands with additional ECL reagents. Then, the Phos-tag-stripped
membrane was washed for 3 h and blocked for 1 h at room tem-
perature with 5% (w/v) ECL blocking agent in TBST. The membrane
was reprobed with the primary antibody for the a1 subunit of
VDCC, rabbit anti-Cav1.2 antibody (1:1000, Alomone Labs, Jerusa-
lem, Israel), and the secondary antibody, HRP conjugated donkey
anti-rabbit IgG antibody (1:1000, GE Healthcare), for 1 h at room
temperature, respectively, and the expression of VDCC was ana-
lyzed, as described above. Densitometry was used to quantify the
amount of phosphorylation of VDCC using Image Quant TL 7.0 soft-
ware (GE Healthcare). In order to determine the band of the phos-
phorylated VDCC (p-VDCC), the superimposed image was
generated from the Phos-tag and VDCC images. Based on the im-
age, a corresponding area was considered as the band of p-VDCC
or VDCC. The amount of phosphorylation of VDCC was calculated
as p-VDCC/VDCC (arbitrary unit). The respective means of the p-
VDCC/VDCC in each group was described as ratio of the control
VSMCs (control = 1).
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The results are expressed as the mean ± S.E. (standard error).
Statistical differences between the two groups were evaluated by
unpaired Student’s t-test. P < 0.05 was considered statistically sig-
niﬁcant. All analyses were performed with Stat View J 5.0 (SAS
Institute Inc., Cary, NC, USA).
3. Results
3.1. The peptide skeleton of Trp-His is crucial for the inhibition of
[Ca2+]i elevation
To examine the effect of Trp-His on elevated [Ca2+]i control in
VSMCs, the cells were incubated with Fura-2/AM, an intracellular
Ca2+-sensitive probe. The application of Ang II (10 lM) to
Fura-2-loaded VSMCs in the presence of AT2R antagonist yielded
a marked increase in [Ca2+]i (D[Ca2+]i: Ang II, 180.0 ± 21.0 nM,
n = 8), which was inhibited by Trp-His (300 lM) (D[Ca2+]i: Trp-
His, 18.8 ± 10.3 nM, n = 4, P < 0.01). In contrast, a mixture of the
corresponding constituent amino acids (i.e., Trp + His, each
300 lM) did not show any signiﬁcant inhibition compared with
the di-peptide Trp-His (D[Ca2+]i: Trp + His, 131.5 ± 15.0 nM, n = 4,
N.S. vs. Ang II) (Fig. 1).
3.2. PLC-activated Ca2+-signaling pathways are involved in
Trp-His-induced [Ca2+]i reduction
To clarify whether Trp-His is involved in the regulation of Ca2+
release from the endoplasmic reticulum/sarcoplasmic reticulumFig. 1. The peptides skelton is required for Trp-His-induced [Ca2+]i regulation in
Ang II-stimulated VSMCs. (A) A real-time [Ca2+]i change in Fura-2-loaded VSMCs
was measured in the absence or presence of Trp-His (300 lM) or a mixture of its
individual constituent amino acids (i.e., Trp + His, each 300 lM). The AT2R
antagonist (PD123177, 1 lM) and the sample were coincubated 10 min prior to
the addition of Ang II. (B) Ang II-induced elevation of [Ca2+]i was indicated as
D[Ca2+]i (P < 0.01 compared with Ang II; n = 4–8).(ER/SR), Fura-2-loaded VSMCs were pretreated with Ca2+-free PSS
buffer (containing 0 mM CaCl2) to avoid [Ca2+]i elevation by extra-
cellular Ca2+ entry and to focus on the elevation from ER/SR in Ang
II-stimulated VSMCs. Trp-His did not reduce the [Ca2+]i elevation
under this assay condition (D[Ca2+]i: Ang II, 87.3 ± 10.8 nM; Trp-
His, 76.6 ± 12.1 nM, n = 5), whereas 2-APB, an inhibitor of inositol
1,4,5-trisphosphate receptor (IP3R), abolished the [Ca2+]i elevation
(D[Ca2+]i: 2-APB, 8.1 ± 1.2 nM, n = 6, P < 0.01 vs. Ang II) (Fig. 2A and
B). Trp-His alone had no power for [Ca2+]i elevation. Fig. 2C and D
showed the changes in [Ca2+]i when the angiotensin type 1 recep-
tor (AT1R)-coupled PLC was activated by m-3M3FBS, a direct PLC
activator [10]. Consequently, m-3M3FBS (20 lM) exhibited the
progressive increase in [Ca2+]i (D[Ca2+]i: m-3M3FBS, 221.8 ±
10.5 nM, n = 3), while U-73122 (a PLC inhibitor, 10 lM) abolished
the [Ca2+]i elevation signiﬁcantly (D[Ca2+]i: U-73122,
10.5 ± 14.6 nM, n = 3, P < 0.01). Interestingly, Trp-His signiﬁcantlyFig. 2. Trp-His inhibited PLC-related Ca2+-pathways, not Ca2+ release from ER/SR.
(A) A real-time [Ca2+]i change in Fura-2-loaded VSMCs was measured in the absence
or presence of Trp-His (300 lM) or 2-APB (200 lM). PD123177 (1 lM) and the
sample were coincubated in Ca2+-free PSS 10 min prior to the addition of Ang II. (B)
Ang II-induced elevation of [Ca2+]i was indicated as D[Ca2+]i (P < 0.01 compared
with Ang II; n = 5–6). (C) A real-time [Ca2+]i change in Fura-2-loaded VSMCs was
measured in the absence or presence of Trp-His (300 lM) or an antagonist of PLC,
U-73122 (10 lM). The sample was coincubated in PSS 10 min prior to the addition
of a PLC activator, m-3M3FBS. (D) The m-3M3FBS-induced elevation of [Ca2+]i was
indicated as D[Ca2+]i (P < 0.01 compared with m-3M3FBS; n = 3).
Fig. 3. Trp-His inhibited the activity of CaMK II. VSMCs were preincubated in the
absence or presence of Trp-His (300 lM) or KN-62 (50 lM) for 10 min. The cells
were stimulated either vehicle or Ang II (10 lM) for 60 min. CaMK II activity (mU/
mg protein) in the VSMC extracts was calculated from standard curves prepared
with serial dilutions of CaMK II (P < 0.05 compared with Ang II; n = 3–5).
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His, 63.2 ± 11.2 nM, n = 3, P < 0.01 vs. m-3M3FBS).
3.3. CaMK II activity in VSMCs was inhibited by Trp-His
Effect of Trp-His on CaMK II activity in Ang II-stimulated VSMCs
for 60 min was examined, since the Ang II/PLC Ca2+-signal pro-
motes the formation of Ca2+-CaM complex to activate CaMK II,
resulting in the direct opening of VDCC or [Ca2+]i elevation
[11,12]. Trp-His or KN-62 (a CaMK II inhibitor) alone did not alter
the CaMK II activity in VSMCs within the experimental conditions
(control, 5.51 ± 0.46 mU/mg protein; Trp-His, 5.00 ± 0.90 mU/mgFig. 4. Trp-His inhibited Ang II-induced phosphorylation of VDCC. VSMCs were preincuba
stimulated with Ang II for 60 min. The densitometric analysis of p-VDCC/VDCC (arbitrary
p-VDCC/VDCC in each group was described as ratio of the control VSMCs (P < 0.05, P < 0protein; KN-62, 5.08 ± 0.26 mU/mg protein, n = 3–5). Fig. 3 also de-
scribed that the addition of Ang II signiﬁcantly activated CaMK II
(Ang II, 7.20 ± 0.36 mU/mg protein, n = 3, P < 0.05 vs. control) and
Trp-His signiﬁcantly lowered CaMK II activity in Ang II-stimulated
VSMCs (Trp-His, 6.21 ± 0.26 mU/mg protein, n = 3, P < 0.05 vs. Ang
II), similar to KN-62 (5.59 ± 0.33 mU/mg protein, n = 3, P < 0.05 vs.
Ang II).
3.4. Trp-His inhibited phosphorylation of VDCC
To conﬁrm the involvement of Trp-His in the CaMK II/VDCC
phosphorylation pathway [13,14], Phos-tag, that has already been
applied for the analysis of phosphorylated potassium channels
[15], was used for the detection of p-VDCC in the present study.
VSMCs were pretreated with either Trp-His or KN-62, and stimu-
lated with Ang II for 60 min. Western blot analysis (Fig. 4) revealed
that both Trp-His and KN-62 had no ability to alter the p-VDCC/
VDCC ratio in VSMCs (control, 1.00 ± 0.04; Trp-His, 0.97 ± 0.12;
KN-62, 0.91 ± 0.08, n = 3). In contrast, in Ang II (10 lM)-stimulated
VSMCs, Trp-His as well as KN-62 signiﬁcantly reduced the p-VDCC/
VDCC ratio (Ang II, 1.12 ± 0.02, P < 0.05 vs. control; Trp-His,
0.92 ± 0.06, P < 0.05 vs. Ang II; KN-62, 0.88 ± 0.04, P < 0.01 vs. Ang
II, each n = 3).
4. Discussion
In this report, we provide the ﬁrst indication of the physiologi-
cal functionality of the anti-atherosclerotic small peptide, Trp-His,
on vessel tone. The peptide skeleton of Trp-His plays a crucial role
in the regulation of elevated [Ca2+]i, by which vasoconstriction (or
cell proliferation) signaling pathways in VSMCs are activated. The
[Ca2+]i experiments using Ang II/PLC agonists or an IP3R antagonist
revealed that the reduction in elevated [Ca2+]i by Trp-His was
caused by suppression of the PLC-related Ca2+-signaling pathways,ted in the absence or presence of Trp-His (300 lM) or KN-62 (50 lM) for 10 min and
unit) was performed using Image Quant TL 7.0 software. The respective means of the
.01 compared with Ang II; n = 3–5).
Fig. 5. Schema of the possible roles of Trp-His on CaMK II-mediated VDCC phosphorylation in VSMCs. We demonstrated that Trp-His inhibited the Ang II-induced activation
of CaMK II and inhibited Ang II-induced phosphorylation of VDCCs. Considering that CaMK II is involved in the phosphorylation of VDCCs followed by the facilitation of Ca2+
inﬂux via VDCCs, these data suggest that Trp-His plays a potential role in the regulation of [Ca2+]i by its blockade of the CaMK II-VDCC phosphorylation pathway. The potential
of Trp-His to act on the Ca2+-CaM/CaMK II signaling pathways remains unclear, and further investigations are currently in progress.
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IP3R pathway. Further experiments in Ang II-stimulated VSMCs
supported that Trp-His attenuated CaMK II activity. The ﬁnding
that Trp-His signiﬁcantly inhibits Ang II-induced phosphorylation
of a1 subunit of VDCC by Phos-tag analysis supports that Trp-His
plays a potential role in the regulation of [Ca2+]i in VSMCs by its
blockade of the PLC/CaMK II-VDCC phosphorylation pathway, as
illustrated in Fig. 5.
A new Ca2+-related signaling pathway, by which CaMK II prefer-
ably phosphorylates the intracellular side of VDCC [13,14], allowed
us to consider the overall mechanism underlying the ability of Trp-
His to reduce [Ca2+]i, since phosphorylation of VDCC promotes the
opening of extracellular Ca2+ inﬂux route across the VSMC mem-
brane [16]. As shown in Fig. 3, Trp-His-treatment of VSMCs signif-
icantly lowered CaMK II activity. There are two possible
mechanisms for the lowering of CaMK II activity by the bioactive
peptide, Trp-His, i.e., direct inhibition of CaMK II and inhibition
of Ca2+-CaM formation leading to CaMK II activation. As for the for-
mer mechanism, it has been reported that longer peptides such as
Lys-Lys-Ala-Leu-Arg-Arg-Gln-Glu-Ala-Val-Asp-Ala-Leu [17] inhib-
ited CaMK II activity. In the latter mechanism, pea protein hydro-
lysate has been reported to inhibit the formation of Ca2+-CaM
complexes [18], although potential candidates (i.e., peptides)
responsible for the action have not been elucidated. Thus, further
investigations are necessary to clarify whether Trp-His can inhibit
CaMK II or Ca2+-CaM formation. In addition, considering that some
subtypes of total protein kinase C (PKCs) may facilitate the phos-
phorylation of VDCC [19], speciﬁc inhibition of the subtypes by
Trp-His must be also included for further investigations.
CaM is a Ca2+-binding protein that possesses four binding sites.
Once Ca2+ binds to CaM, it causes a dramatic change in the struc-
tural conformation, known as EF hands [20]. The binding sites of
Ca2+ to CaM are mainly composed of Asp and Glu, which means
that the binding domains of CaM are highly negative [20]. As pKa
of imidazole in His is 6.0 [21], Trp-His itself may occur as an equi-
libriummixture of the peptide bearing the uncharged and positive-
charged moieties at physiological pH. Although further detailed
investigations on the mechanism of the Trp-His-induced [Ca2+]i
reduction are needed, the CaM-binding ability of Trp-His to pre-
vent Ca2+-CaM formation cannot be ruled out as once such mech-
anism in VSMCs. The conﬁguration and/or sequence of peptides
can drastically affect their inhibitory potential on [Ca2+]i regulationin VSMCs. Our previous ﬁnding that His-Trp, the reversed sequence
of Trp-His, evoked a reduction of [Ca2+]i similar to Trp-His [3] sug-
gested that the amino acid residues would be essential for the ac-
tion. From these ﬁndings, the imino group and/or indole moiety of
Trp-His may be responsible for the suppression of the PLC/CaMK II/
VDCC phosphorylation pathway. Studies on structure-activity rela-
tionship using Trp-His analogues are currently in progress using
Ang II-stimulated VSMCs.
In conclusion, we demonstrated for the ﬁrst time that evena
di-peptide, Trp-His, that has been shown to have an anti-
atherosclerotic effect in vivo and to reduce [Ca2+]i in AngII-
stimulated VSMCs, has the potential to suppress the
PLC/Ca2+-CaM/CaMK II/VDCC phosphorylation pathway, likely
through inhibition of the formation of Ca2+-CaM complexes and/
or CaMK II activity in VSMCs. The involvement of Trp-His in such
Ca2+-signaling pathways should be, thus, addressed to allow new
insights of the vasophysiological functionalities of small peptides.
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